Journal
DIABETOLOGIA
Volume 66, Issue 4, Pages 754-767Publisher
SPRINGER
DOI: 10.1007/s00125-022-05851-x
Keywords
Empagliflozin; Insulin resistance; Obesity; SGLT2 inhibition; Skeletal muscle mitochondria; Steatosis; Western-type diet
Categories
Ask authors/readers for more resources
This study aimed to test whether empagliflozin can prevent weight gain and metabolic dysfunction in a mouse model of diet-induced obesity and insulin resistance. The results showed that empagliflozin supplementation prevented diet-induced metabolic abnormalities and protected mice from obesity, insulin resistance, and fatty liver. Furthermore, empagliflozin supplementation improved mitochondrial morphology in skeletal muscle.
Aims/hypothesis: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used in the treatment of type 2 diabetes, heart failure and chronic kidney disease. Their role in the prevention of diet-induced metabolic deteriorations, such as obesity, insulin resistance and fatty liver disease, has not been defined yet. In this study we set out to test whether empagliflozin prevents weight gain and metabolic dysfunction in a mouse model of diet-induced obesity and insulin resistance. Methods: C57Bl/6 mice were fed a western-type diet supplemented with empagliflozin (WDE) or without empagliflozin (WD) for 10 weeks. A standard control diet (CD) without or with empagliflozin (CDE) was used to control for diet-specific effects. Metabolic phenotyping included assessment of body weight, food and water intake, body composition, hepatic energy metabolism, skeletal muscle mitochondria and measurement of insulin sensitivity using hyperinsulinaemic-euglycaemic clamps. Results: Mice fed the WD were overweight, hyperglycaemic, hyperinsulinaemic and insulin resistant after 10 weeks. Supplementation of the WD with empagliflozin prevented these metabolic alterations. While water intake was significantly increased by empagliflozin supplementation, food intake was similar in WDE- and WD-fed mice. Adipose tissue depots measured by MRI were significantly smaller in WDE-fed mice than in WD-fed mice. Additionally, empagliflozin supplementation prevented significant steatosis found in WD-fed mice. Accordingly, hepatic insulin signalling was deteriorated in WD-fed mice but not in WDE-fed mice. Empagliflozin supplementation positively affected size and morphology of mitochondria in skeletal muscle in both CD- and WD-fed mice. Conclusions/interpretation: Empagliflozin protects mice from diet-induced weight gain, insulin resistance and hepatic steatosis in a preventative setting and improves muscle mitochondrial morphology independent of the type of diet.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available